• Home
  • About Us
  • Contact US !
Incitasecurity
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car
No Result
View All Result
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car
No Result
View All Result
Incitasecurity
No Result
View All Result
Home Uncategorized

Promising new melanoma drug in the offing

onkar by onkar
November 29, 2015
in Uncategorized
0
VIEWS
Share on FacebookShare on Twitter
Promising new melanoma drug in the offing
Scientists have discovered a new compound that shows promise for treating deadly skin cancers like melanoma that are resistant or unresponsive to leading therapies today.

The new compound, named SBI-756, targets a specific molecular machine known as the translation initiation complex.

These structures are in every cell and play the critical role of translating mRNA into proteins.

In cancer cells the complex is impaired, producing extra protein and providing a growth advantage to tumours.

SBI-756 causes the translation complex to dissociate, and was shown to inhibit melanoma cell growth, said scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP).

“The unique target of SBI-756 makes it especially promising for use in combination therapy,” said Ze’ev Ronai, senior author and scientific director of SBP’s La Jolla campus in California.

A major issue limiting the effectiveness of current melanoma therapies is that tumours become resistant to treatment.

“Combining drugs that come at a melanoma from different angles may help overcome the problem of drug resistance,” Ronai added.

About 50 percent of melanomas are caused by mutations in a specific gene called BRAF.

The team found that if SBI-756 is co-administered with vemurafenib, a BRAF inhibitor, the tumours disappeared and most importantly, they did not reoccur.

Even in mice with advanced/late stage skin cancer, the reappearance of resistant tumours was slowed by including SBI-756.

These data suggests that SBI-756 provides a significant advantage in overcoming tumour resistance.

“The ability of this compound to delay or eliminate the formation of resistant melanomas is very exciting,” Ronai added.

The team is now testing whether combining SBI-756 with existing drugs used for treating these types of melanomas can make the tumours disappear.

The paper was published in the journal Cancer Research.

[“source-timesofindia.indiatimes”]
Tags: drug in the offingPromising new melanoma
Previous Post

Air pollution puts diabetics at high heart disease risk

Next Post

Tips to reduce your risk of prostate cancer

Next Post
Tips to reduce your risk of prostate cancer

Tips to reduce your risk of prostate cancer

Recent Post

  • Revitalize Your Fitness Journey with Acid Bath CrossFit: Embrace the Intensity and Achieve Peak Performance
  • Unleashing Festive Fitness: The CrossFit 12 Days of Christmas Workout Extravaganza
  • Unleash Your Inner Strength: Acid Bath CrossFit for Ultimate Fitness Transformation
  • Crushing the 23.1 CrossFit Open: Unleashing Your Winning Strategy
  • Unleashing Strength and Power: The Inspiring Journey of Paige Powers in CrossFit
  • Unleashing Strength and Endurance: Helen’s CrossFit Challenge
  • Mike Wassmer: Rising Star of CrossFit Dominates the Fitness Arena
  • Unleash Your Inner Athlete: Diane CrossFit Workout for Strength and Stamina
  • 5 Challenging CrossFit WODs with Kettlebell Swings to Boost Your Fitness Level
  • Power Up Your Game with CrossFit Football Workouts: A Comprehensive Guide
Incitasecurity

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Navigate Site

  • Home
  • About Us
  • Contact US !

Follow Us

No Result
View All Result
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.